A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission
We would like to thank Angelo Willems and Carine Seynaeve for their expert technical assistance. The work was financially supported by the International Myeloma Foundation, Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO-Vl), Stichting tegen Kanker, King Baudouin Foundation, Multiple Myeloma Research Foundation, the European Stem cell network (EUFP6 MSCNET) and the Onderzoeksraad Vrije Universiteit Brussel (GOA48, OZR-VUB). E Van Valckenborgh, E Menu and E De Bruyne are postdoctoral fellows, and E Schouppe and K Movahedi are predoctoral fellows of FWO-Vl. JA Van Ginderachter is supported by Stichting tegen Kanker. OT-1 mice were a kind gift of Dr Muriel Moser (ULB, Brussels, Belgium). Non-labeled antiCCR2 (MC-21) was a gift of Dr Matthias Mack (University of Regensburg, Germany).